Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial - Wikidata - wikimedia - TriplyDB

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

http://www.wikidata.org/entity/Q56897633

about

Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics Immunotherapy for lung cancer: advances and prospects Cancer immunotherapy: the beginning of the end of cancer?Targeted drugs in small-cell lung cancer Small cell lung cancer (SCLC): no treatment advances in recent years Cancer stem cells in small cell lung cancer Cellular and molecular biology of small cell lung cancer: an overview Novel therapies in small cell lung cancer Advances in immunotherapy for treatment of lung cancer Research Progression of Maintenance Therapy in Small Cell Lung Cancer Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy Genomic profiling of small-cell lung cancer: the era of targeted therapies Progress in immunotherapy for non-small cell lung cancer Combining radiation and immunotherapy: a new systemic therapy for solid tumors?Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications Update on the challenges and recent advances in cancer immunotherapy The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment Advances of immunotherapy in small cell lung cancer Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?The interplay of immunotherapy and chemotherapy: harnessing potential synergies Immune checkpoint blockade: a common denominator approach to cancer therapy Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review.Antibody Therapies in Cancer.Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data.Consolidative thoracic radiotherapy for extensive stage small cell lung cancer Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors Small cell lung cancer: where do we go from here?Small cell lung cancer: therapies and targets The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014 Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?Immune checkpoint inhibitors in NSCLC.Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome.Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 Classification of current anticancer immunotherapies

P2860

Q26738673-AE9B20EE-FB04-4BCA-A274-3DA817984560 Q26738677-7603FEEF-F200-4E66-B8B8-0449FEA829A5 Q26750617-39A890C5-AC56-4E4F-8B01-D642AA0452D9 Q26752277-4AA593C0-8AE9-45B5-8A57-033738F36515 Q26767017-F71AB87D-1005-42BC-BEFD-A50C4581417F Q26767020-3C984FF6-AAAF-4B57-8F9E-A6BEE224335F Q26767026-1248937A-F2DB-450C-BBA9-BA03B2F5C60A Q26767029-CBE421DE-6C30-4F69-865A-14C0283359DE Q26775390-898F71E0-177C-494A-A033-055B6F72C589 Q26778790-7455E96F-7D9B-4E9E-BB63-C69DDAB836DC Q26783450-D7CF35D4-BE83-42C5-A3EA-B4B9324CA5DC Q26795509-AE1D1C57-7183-4A5D-84BB-39197FB0AA05 Q26796309-E84CFB9D-87F7-4482-AE50-A8080B60CC35 Q26826915-B4B657CC-8C83-4D55-BD43-0006EB8387BD Q26865725-C4B96DD3-FD01-44B8-8AC4-3A47F5876575 Q26991721-1E2FF40A-5EB0-40E0-AA6D-F8177B0F8264 Q26996518-67CD3B2D-BB46-4C10-A66E-A6995406BFE4 Q27014693-107C3AD9-143E-48FD-A3DB-8C9EECEDB254 Q27022789-A4889C3A-7565-4C76-A9CF-0ECBA38D4228 Q27027662-E290E932-1985-4EFA-8708-9A923F87AA00 Q28066199-03CC4FC6-A011-4C70-9FF8-A9A739878D2B Q28069422-7C38B3FD-6F2C-478E-B892-54525CED852D Q28071998-1124E7BB-B593-429A-A45A-3A852E040398 Q28079771-10466082-53EA-495C-9673-6F7E6F0C4F20 Q28081893-B5CBBC13-3CEB-4BAA-9FD0-7944F73D7ABA Q28083981-17FEE352-5ACB-47D8-A3A5-1849762820D3 Q30235360-537FA696-AE03-4903-95A7-5A624500BC63 Q31104000-9041F995-77CE-45F9-A9AF-0F943B9222FA Q31171172-570D8E7A-A3F9-4901-95FF-A784C2F3BC12 Q33591894-0100524F-6602-48EB-B5E1-8B70AD7A73E7 Q33645601-0E93690C-9F29-4002-9D78-06EE40F69B26 Q33872327-22EBDD98-DC89-411A-8851-AC164C165555 Q34250859-FA280C7B-AD26-4E22-B8B5-4365AC17FFE4 Q34402325-470B0657-2DC7-4EE4-BD89-455653BB45A1 Q34406469-84076516-6742-49A1-9523-81BA342AB730 Q34437570-3E29754E-E491-4D7B-822C-0426DA30384C Q34537285-B6E7A4DB-CD51-4C0F-A7B9-1D66313C3420 Q34951157-60067A3B-E6DF-477F-8F6F-CDF8C850FFD7 Q35136424-F7E194A0-19F0-4E44-9570-57F771F655C1 Q35149637-58C7A0D2-73D1-40D7-B0BD-B9B5814AABCE

P2860

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

http://www.wikidata.org/entity/Q56897633

description

im Januar 2013 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 02 August 2012

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в січні 2013

@uk

name

Ipilimumab in combination with ...... ind, multicenter phase 2 trial

@en

Ipilimumab in combination with ...... ind, multicenter phase 2 trial

@nl

type

label

Ipilimumab in combination with ...... ind, multicenter phase 2 trial

@en

Ipilimumab in combination with ...... ind, multicenter phase 2 trial

@nl

prefLabel

Ipilimumab in combination with ...... ind, multicenter phase 2 trial

@en

Ipilimumab in combination with ...... ind, multicenter phase 2 trial

@nl

P1433

Q56897633-30C277A3-0F7D-4B7A-8D4F-E26AD2CAC7FF

P1476

Q56897633-A11BA4C9-E2E1-4E6C-A961-3AB47E9FE23C

P2093

Q56897633-1DA28F1F-7084-4422-9F54-8531EEBC5BB7

Q56897633-212F969B-4F78-4975-912B-51291A4E0F7C

Q56897633-273C68AB-5ADD-47B3-BA53-627A48D1C3DC

Q56897633-33EF3D90-33DA-4402-88EE-1640F898B6C2

Q56897633-4CC39C21-9986-44A1-BBB6-3EA3B4498399

Q56897633-67E39585-CACB-4E52-80E4-93345ABA1789

Q56897633-8916F58C-9185-4A41-8C42-E37D9F4B2800

Q56897633-BCD55564-4436-4659-AA3C-AE6A7D6990E3

Q56897633-E1990B87-B3BA-4C4D-AF53-13A392C9685C

P2860

Q56897633-064FDC04-D00D-4B1E-B9B2-F44EB9E542B2

Q56897633-0B0F6763-AA3A-42F2-89E7-FE2FD8E7020B

Q56897633-137ADAA8-0BE2-4113-B7FF-D10D8009B718

Q56897633-1C0402D3-4BEF-4FC2-A006-18BB881CDE72

Q56897633-20F1B253-88F2-43C8-B7D4-108882A7770C

Q56897633-27CB9F67-C590-4B07-B6AD-986AC8113ABB

Q56897633-2A6DEF77-D6DA-4A48-BD61-955044FA1DA1

Q56897633-2DDEEE14-1D2D-4C74-858D-F928E6185360

Q56897633-39CF0D55-85CD-461C-A666-20FF9BAE3CDD

Q56897633-3ACD76D4-73CF-4D19-85E4-A609E2EE829F

P304

Q56897633-BD7CFD91-09F2-4C29-99F7-23AF2B26D898

P31

Q56897633-76C85987-CBDC-4EC4-9CCB-3C490356FA47

P356

Q56897633-B0FF2324-FE4D-4129-962C-40C5FBD46374

P407

Q56897633-03839272-014F-4E57-AD9E-B8E201B33AEF

P433

Q56897633-56059899-B1A4-4EF4-944C-1246E25A5999

P478

Q56897633-244D24E7-2FA0-4F0F-AFE0-659ADEB0BFDD

P50

Q56897633-D8CF7C40-04FD-4040-AE22-1E729B99CB88

P577

Q56897633-A4A87FD4-8546-405F-9036-5101F59464D1

P698

Q56897633-09FBC5C6-7E7E-48EA-A57D-CD7EB08D53C7

P356

P1433

Annals of Oncology

P1476

Ipilimumab in combination with ...... ind, multicenter phase 2 trial

@en

P2093

A Luft

http://www.w3.org/2001/XMLSchema#string

F Barlesi

http://www.w3.org/2001/XMLSchema#string

H Lu

http://www.w3.org/2001/XMLSchema#string

J-M Cuillerot

http://www.w3.org/2001/XMLSchema#string

M Reck

http://www.w3.org/2001/XMLSchema#string

M Sebastian

http://www.w3.org/2001/XMLSchema#string

P Serwatowski

http://www.w3.org/2001/XMLSchema#string

R Chacko

http://www.w3.org/2001/XMLSchema#string

T J Lynch

http://www.w3.org/2001/XMLSchema#string

P2860

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

CTLA-4 can function as a negative regulator of T cell activation

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Enhancement of antitumor immunity by CTLA-4 blockade

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Reporting results of cancer treatment

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.

P304

75-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDS213

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Igor N. Bondarenko

P577

2012-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22858559

http://www.w3.org/2001/XMLSchema#string